Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation
نویسندگان
چکیده
منابع مشابه
Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare, but aggressive endocrine malignancy with a generally poor clinical outcome. There is no effective therapy for advanced and metastatic ACC. In our study, we found that an existing drug (rottlerin) exerted its tumour-suppressive function in ACC. Specifically, rottlerin inhibited cellular proliferation of ACC cell lines (NCI-H295R and SW-13) in a dose- and...
متن کاملPodophyllotoxin: a novel potential natural anticancer agent
Objective: The aim of the present review is to give an overview about the role, biosynthesis, and characteristics of Podophyllotoxin (PTOX) as a potential antitumor agent with particular emphasis on key biosynthesis processes, function of related enzymes and characterization of genes encoding the enzymes. Materials and Methods: Google scholar, PubMed and Scopus were searched for literatures wh...
متن کاملTranscriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
PURPOSE Hepatocellular carcinoma (HCC) is the sixth most common solid tumor worldwide and the third leading cause of cancer-related death. HCC is a particularly serious threat to the Chinese population. Although many molecular alterations are known to be involved in the tumorigenesis of hepatocytes, no systemic survey has examined the somatic mutations in HCC samples from Chinese patients. Our ...
متن کاملCutaneous metastasis in a patient with adrenocortical carcinoma
Adrenocortical carcinoma is an uncommon and aggressivemalignancy. Despite a high frequency of metastasis, cutaneousmetastasis of adrenocortical carcinoma is rare with only isolatedcase reports. Its diagnosis can be challenging based solely onhistopathological findings. Yet, the clinical history in combinationwith an immunohistochemical panel consisting of inhibin,vimentin, chromogranin, synapto...
متن کاملNutlin-3a is a potential therapeutic for ewing sarcoma.
PURPOSE Although mutations in the TP53 gene occur in half of all cancers, approximately 90% of Ewing sarcomas retain a functional wild-type p53. The low frequency of TP53 alterations in Ewing sarcoma makes this tumor type an ideal candidate for p53-targeted therapies. In this study, we have examined the molecular and cellular responses of cultured Ewing sarcoma cell lines following exposure to ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Medicine
سال: 2018
ISSN: 2045-7634
DOI: 10.1002/cam4.1431